CD22 and acute lymphoblastic leukemia: In addition, the 2020 American Society of Hematology (ASH) annual meeting announced two studies about FasT CAR-T cells, including CD19-CD22 FasT dual-targeting CAR-T cells (GC022F) in B-ALL patients and BCMA-CD19 FasT dual-targeting CAR-T cells (GC012F) in R/R MM patients (12, 13).